Seres Therapeutics Inc. (NASDAQ: MCRB) is 610.14% higher on its value in year-to-date trading and has touched a low of $2.52 and a high of $38.50 in the current 52-week trading range. The MCRB stock was last observed hovering at around $26.25 in the last trading session, with the day’s loss setting it -1.75% off its average median price target of $41.00 for the next 12 months. It is also 50.0% off the consensus price target high of $49.00 offered by 8 analysts, but current levels are -2.08% lower than the price target low of $24.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $24.50, the stock is -1.33% and -15.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.84 million and changing -6.67% at the moment leaves the stock 52.00% off its SMA200. MCRB registered 631.34% gain for a year compared to 6-month gain of 390.98%. The firm has a 50-day simple moving average (SMA 50) of $27.24 and a 200-day simple moving average (SMA200) of $21.64.
The stock witnessed a -7.02% loss in the last 1 month and extending the period to 3 months gives it a -11.55%, and is -4.03% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.81% over the week and 7.78% over the month.
Seres Therapeutics Inc. (MCRB) has around 108 employees, a market worth around $2.40B and $23.30M in sales. Distance from 52-week low is 872.22% and -36.36% from its 52-week high. The company has generated returns on investments over the last 12 months (303.30%).
Seres Therapeutics Inc. (MCRB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Seres Therapeutics Inc. (MCRB) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.00, where 2 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Seres Therapeutics Inc. is expected to release its quarterly report on 05/06/2021 and quarterly earnings per share for the current quarter are estimated at -$0.28 with sales reaching $6.92M over the same period.The EPS is expected to grow by 48.90% this year, but quarterly earnings will post -34.60% year-over-year. Quarterly sales are estimated to shrink -9.20% in year-over-year returns.
Seres Therapeutics Inc. (MCRB) Top Institutional Holders
165 institutions hold shares in Seres Therapeutics Inc. (MCRB), with 8.45M shares held by insiders accounting for 9.26% while institutional investors hold 89.47% of the company’s shares. The shares outstanding are 83.53M, and float is at 82.80M with Short Float at 5.48%. Institutions hold 81.19% of the Float.
The top institutional shareholder in the company is Flagship Pioneering Inc. with over 21.57 million shares valued at $610.7 million. The investor’s holdings represent 23.64% of the MCRB Shares outstanding. As of Sep 29, 2020, the second largest holder is ARK Investment Management, LLC with 12.29 million shares valued at $348.02 million to account for 13.47% of the shares outstanding. The other top investors are FMR, LLC which holds 10.72 million shares representing 11.75% and valued at over $303.41 million, while Blackrock Inc. holds 6.60% of the shares totaling 6.02 million with a market value of $170.46 million.
Seres Therapeutics Inc. (MCRB) Insider Activity
The most recent transaction is an insider sale by Henn Matthew R.. SEC filings show that Henn Matthew R. sold 91,812 shares of the company’s common stock on Dec 01 at a price of $27.04 per share for a total of $2.48 million. Following the sale, the insider now owns 0.0 shares.
Seres Therapeutics Inc. (MCRB): Who are the competitors?
The company’s main competitors (and peers) include Acceleron Pharma Inc. (XLRN) that is trading 143.19% up over the past 12 months. Short interest in the company’s stock has fallen -11.67% from the last report on Nov 12, 2020 to stand at a total of 5.07 million short shares sold with a short interest ratio of 4.5.